Pieris Obtains Regulatory Clearance for Clinical Study in Australia

Pieris Pharmaceuticals (NASDAQ:PIRS) announced it received approval from the Human Research Ethics Committee and authority from the Therapeutic Goods Administration to start an in-human study for PRS-060/AZD1402 in Australia.
As quoted in the press release:

This phase 1 study will be conducted in healthy subjects and is being developed as part of Pieris’ strategic alliance with AstraZeneca, which is funding the trial, with Pieris being responsible for conducting the study.
“We look forward to dosing the first subject in our first clinical trial for PRS-060/AZD1402 by year end, triggering a milestone payment by AstraZeneca to Pieris,” commented Stephen S. Yoder, President and CEO of Pieris. “This program represents the first inhaled Anticalin protein to enter clinical development and will cap an ambitious year of pipeline progression, which included the clinical initiation of PRS-343, our lead immuno-oncology bispecific program.”

Click here to read the full press release.

Source: www.marketwired.com